Articles from CorriXR Therapeutics, Inc.

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a manuscript in Molecular Therapy Oncology detailing results from a preclinical study evaluating CRISPR-directed gene editing for the treatment of squamous cell lung carcinoma (LUSC). The study was conducted in collaboration with scientists at ChristianaCare’s Gene Editing Institute (GEI).

CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriXR’s lead program aimed at developing next-generation treatments for solid tumors, with particular focus on head and neck, and lung cancers. This investment not only underscores the potential of CorriXR’s cutting-edge therapies but also highlights Delaware’s commitment to supporting innovative early-stage companies.

CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer.

CorriXR Therapeutics, Inc., a leading biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, has announced that Eric B. Kmiec, Ph.D., the company's founder and chief scientific officer, will assume the role of chief executive officer.

CorriXR Therapeutics, Inc. (“CorriXR”), a biotherapeutics company developing unique genetic medicines that optimize the effectiveness of existing cancer treatments by knocking out genes responsible for resistance, today announced the appointment of Jill Castilla to its Board of Directors. Ms. Castilla brings visionary leadership as a nationally recognized innovator in finance and banking.

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company developing breakthrough technology that overcomes drug resistance in solid tumors, announced that Deborah Moorad, MBA, has been named the company’s new chief executive officer. Moorad, who previously served as CEO of Nature Technology Corp., and is an Entrepreneur-in-Residence at Cortado Ventures, succeeds co-founder Eric B. Kmiec, Ph.D., who has been appointed chief scientific officer.